HR 4837, the Written Informed Consent Act, requires the Veterans Health Administration (VHA) to update its existing directive on informed consent to include additional medication classes. Specifically, it mandates that written informed consent must be obtained before prescribing antipsychotics, stimulants, antidepressants, anti-anxiety medications (anxiolytics), and narcotics (opioids) to veterans. This expansion directly affects veterans receiving these medications through the VA system, ensuring they are informed about specific treatment risks and alternatives. The key mechanism is amending VHA Directive 1005 to broaden its application beyond long-term opioid therapy to cover the newly listed medication types.
HR 4611 (EACH Act of 2025) requires all federally funded health programs - including Medicaid, Medicare, military health plans, and the Indian Health Service - to cover abortion services without restrictions, repealing the Hyde Amendment's long-standing ban on federal funding for most abortions. This directly affects millions of people enrolled in these programs, particularly low-income women, women of color (including 25% of Black women and 22% of Hispanic women on Medicaid), and young people. The bill mandates coverage in all federally administered health plans and prohibits state or private insurers from restricting abortion coverage in health insurance. It aims to eliminate current federal and state barriers that deny abortion access to people who rely on government health programs.
HR 1404, the CHAMPVA Children’s Care Protection Act of 2025, expands healthcare eligibility under the CHAMPVA program for children of veterans. It increases the maximum age for children to receive medical benefits from 21 to 26 years old, regardless of marital status. This change directly affects dependent children of veterans who were previously eligible until age 21, extending coverage through their mid-twenties. The policy amendment applies to medical care provided on or after the bill’s enactment date.
HR 6908, the Blue Envelope Awareness Act, creates a new program to help people with speech, hearing, or developmental disabilities communicate more effectively with police during traffic stops. The bill directs federal Byrne grant funds to support "blue envelope programs," which provide individuals with blue envelopes containing disability documentation to show officers and train law enforcement on interacting with these individuals. It amends existing law to define "blue envelope program" and add this funding authorization to the Omnibus Crime Control and Safe Streets Act. The bill directly affects people with disabilities who interact with police and law enforcement agencies receiving Byrne grants.
HR 6859, the HOTDOG Act, requires the Federal Trade Commission (FTC) to study concession pricing at venues that received public funding (like tax credits or bonds) and host events 5+ days yearly. The study will compare food and drink prices inside these venues to nearby community prices, examine pricing practices like dynamic pricing, and assess how well venues disclose prices before purchase. The FTC must complete this study within 90 days and submit a report with findings and recommendations to Congress within one year. This bill directly affects major sports arenas and concert venues using public subsidies, focusing on transparency and affordability without setting immediate price rules.
HR 3492, the Protect Children’s Innocence Act, makes it a federal crime to perform genital or bodily mutilation or chemical castration on minors under 18, except for specific medical reasons. The bill broadly defines prohibited procedures to include gender transition-related surgeries (like hysterectomies or mastectomies) and medical treatments such as puberty blockers or cross-sex hormones administered to minors. It criminalizes these acts when they occur across state lines, involve payments, or use interstate commerce, while explicitly banning religious tradition as a defense. Exceptions include medically necessary procedures for health emergencies, childbirth, or conditions certified by a physician.
HRES 955 is a symbolic House resolution recognizing the importance of maintaining U.S. leadership in ending pediatric HIV/AIDS globally. It affirms support for existing programs like PEPFAR and the Global Fund, which provide critical prevention services (e.g., antiretroviral prophylaxis for pregnant women) and treatment for children. The resolution specifically calls for continued commitment to closing the treatment gap for children, expanding access to long-acting prevention methods, and advancing the Global Alliance to End AIDS in Children by 2030. As a recognition measure, it does not create new laws or allocate funding but underscores ongoing U.S. efforts to prevent mother-to-child transmission and improve pediatric HIV outcomes.
S 3543, the Trade Cheating Restitution Act of 2025, modifies how interest from antidumping and countervailing duties is distributed to eligible businesses. It updates the reference date for interest calculations from October 1, 2014, to October 1, 2000, and creates a special distribution process for interest accrued before the bill's enactment. Eligible businesses must have previously received distributions under the 2000 Continued Dumping and Subsidy Offset Act, file timely certifications, and meet historical eligibility criteria. The bill mandates pro-rata distributions of this interest by the U.S. Customs and Border Protection within 210 days of enactment, split between interest from 2010 onward and 2000-2010.
This bill expands Medicare coverage to include peer support services for beneficiaries with mental health conditions or substance use disorders. It requires Medicare to cover these services when provided by certified peer support specialists at community mental health centers, rural health clinics, or similar facilities. Peer support specialists must be individuals recovering from similar conditions and certified under specific guidelines. The policy change takes effect January 1, 2027, directly affecting Medicare beneficiaries seeking these services and the certified providers offering them.
The ENFORCE Act strengthens federal laws against child exploitation by clarifying what constitutes producing child pornography and removing time limits for prosecuting certain crimes involving child sexual abuse material. It adds these offenses to sex offender registration requirements, prohibits reproducing abusive images during legal proceedings, and creates a presumption for detainment before trial for violations. The bill directly affects federal prosecutors, courts handling these cases, sex offenders subject to registration, and victims whose images are involved. Key changes include ensuring evidence remains under court control and allowing victims access to depictions in the same manner as victims of child pornography cases.
This bill repeals an outdated requirement from the 2006 Post-Katrina Emergency Management Reform Act that restricted how FEMA could award emergency contracts without bidding. It directly affects FEMA's contracting process during disasters, allowing the agency to enter contracts without soliciting bids under urgent circumstances. The bill requires the Secretary of Homeland Security to submit annual reports detailing the number, cost, and purpose of these emergency contracts, as well as how the repeal prevented waste, fraud, and saved taxpayer money. These reports must cover contracts entered during specific periods and include details about the states and disasters involved. The law aims to streamline emergency contracting while adding transparency through mandatory reporting.
FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications, and may make other changes to the regulations as appropriate. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.
